Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Year | Receivables | Debt | Liabilities | Assets | Current Assets |
---|---|---|---|---|---|
2023 | 20.14 M | -36,131,443 | 233.01 M | 464.11 M | 258.22 M |
2022 | 19.91 M | -90,788,817 | 105.03 M | 223.4 M | 190.98 M |
2021 | 16.02 M | -49,571,847 | 165.37 M | 299.98 M | 249.78 M |
2020 | 1.84 M | -107,497,121 | 108.45 M | 279.23 M | 180.64 M |
2019 | 2.29 M | -144,403,318 | 51.77 M | 232.07 M | 207.04 M |